| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Daratumumab in combination with lenalidomide and dexamethasone |
| Brand | Darzalex® |
| Indication | For the treatment of adult patients with multiple myeloma wo have received at least one prior therapy. |
| Assessment Process | |
| Rapid review commissioned | 09/10/2017 |
| Rapid review completed | 27/11/2017 |
| Rapid review outcome | A full pharmacoeconomic evaluation is recommended |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.